Prism Medico & Pharmacy has scheduled its 24th Annual General Meeting (AGM) for Saturday, September 19, 2026. The company seeks shareholder approval for a strategic investment of up to ₹23 crore in M/s. Infuze Well Private Limited (IWPL). This follows a Board of Directors meeting held on Monday, August 24, 2026, at its registered office in Sirmaur, Himachal Pradesh.

The session concluded with the approval of the Director’s Report and annexures for the financial year ended March 31, 2026. This approval paves the way for the announcement of the company’s annual financial results and the finalization of the AGM agenda.

Annual General Meeting Details

The board fixed the date for the AGM as Saturday, September 19, 2026. The meeting will be conducted via Video Conferencing or Other Audio-Visual Means, starting at 12:30 pm.

Key logistical dates approved by the board include:

• Register Closure: The Register of Members and Share Transfer Books will remain closed from September 13, 2026, to September 19, 2026 (both days inclusive).
• E-Voting Cut-off: September 12, 2026, is the cut-off date for shareholders to record their entitlement to cast electronic votes.
• Scrutinizer: Mr. Mast Ram Chechi, proprietor of M/s. M. R. Chechi and Associates (Company Secretaries, Chandigarh), was appointed as the scrutinizer for the e-voting process.

E-Voting Schedule

Shareholders can participate in remote e-voting during the specified window. The timeline is as follows:

Auditor Appointments

The board considered and recommended the following auditor appointments:

• Statutory Auditors: Re-appointment of M/s. Garg Mendiratta and Associates (Chartered Accountants) with remuneration fixed.
• Secretarial Auditors: Appointment of M/s. SDK & Associates (Practicing Company Secretaries) for five financial years, from FY27 to FY31.

Preferential Issue Variation and Strategic Investment

A significant corporate governance update was the approval of a variation in the objects of the Preferential Issue and the utilization of its proceeds. This change modifies the terms originally approved by members in the Extraordinary General Meeting held on March 20, 2026.

The board proposed diverting ₹23 crore of the preferential issue proceeds—originally earmarked for plant machinery and civil structures—to acquire a controlling stake in IWPL. IWPL is setting up a Large Volume Parenteral (LVP) manufacturing facility in Naraingarh, Haryana.

Transaction Details

The investment constitutes a material related party transaction as IWPL is wholly owned by Mrs. Sakshi Laller, Whole-Time Director of Prism Medico, and her immediate family. Mrs. Laller holds 19.40% of IWPL’s paid-up equity share capital. Consequently, related parties are required to abstain from voting on this resolution.

The deployment of proceeds towards this revised object is contingent upon the receipt of balance consideration payable on the exercise of convertible warrants allotted in the earlier preferential issue. The company has received ₹17.5 crore till date against the total ₹25 crore raised, with ₹7.5 crore remaining to be realized upon warrant exercise.

Additionally, the board recommended investing the company’s funds in accordance with Section 186 of the Companies Act, 2013, noting that the proposed investment exceeds the statutory limits prescribed under Section 186(2).

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Prism Medico & Pharmacy Limited reported a net loss of ₹5.83 lakh for the first quarter of FY27 (Q1FY27), ending June 30, 2026, compared to a net profit of ₹65.73 lakh in Q1FY26. The Board of Directors approved the unaudited standalone financial results on August 12, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by Garg Mendiratta & Associates, the statutory auditors.

The company recorded zero revenue from operations in Q1FY27, a sharp contrast to the ₹158.87 lakh generated in the same quarter last year and ₹28.14 lakh in the immediately preceding quarter (Q4FY26). Total income for the quarter was ₹9.06 lakh, derived entirely from other income, which rose significantly from ₹0.04 lakh in Q1FY25. This lack of operational revenue highlights a potential pause or seasonal fluctuation in core business activities during the period.

Total expenses for the quarter amounted to ₹14.89 lakh, up from ₹93.84 lakh in Q1FY25 but higher than the ₹40.64 lakh seen in Q4FY26. Employee benefit expenses accounted for ₹1.77 lakh, while other expenses constituted the largest portion at ₹13.02 lakh. Finance costs remained negligible at ₹0.02 lakh, and depreciation and amortization expenses were ₹0.09 lakh. The profit before tax stood at a loss of ₹5.83 lakh, with no current or deferred tax expenses recorded for the quarter.

What the Numbers Show

The most striking feature of the Q1FY27 results is the complete absence of revenue from operations, which had been ₹158.87 lakh in the same quarter last year. While total expenses decreased substantially year-on-year due to lower material consumption (which was nil in both Q1FY27 and Q4FY26), the fixed costs such as employee benefits and other expenses continued to accrue. The shift from a net profit position in Q1FY26 to a net loss in Q1FY27 underscores the impact of the revenue gap. Additionally, paid-up equity share capital increased to ₹1,356.34 lakh from ₹606.34 lakh in previous periods, indicating a recent capital raise or bonus issue that has not yet translated into operational revenue generation in this quarter.